| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Zoladex | AstraZeneca | Radiance Pharmaceuticals Limited | 3.6mg | 1 | Injection | KES 12,137.00 | |
| Zoladex | AstraZeneca | Radiance Pharmaceuticals Limited | 10.8mg | 1 | Injection | KES 26,079.00 |
| Goserelin acetate More info | |
|---|---|
| Mode Of Action | Synthetic decapeptide analogue of luteinizing hormone-releasing hormone (gonadotropin releasing hormone, GnRH, agonist analogue). Its initial administration stimulates release of gonadotropins, LH and FSH, from the anterior pituitary. This is followed by their suppression. |
| Drug Indication | Synthetic decapeptide analogue of luteinizing hormone-releasing hormone (gonadotropin releasing hormone, GnRH, agonist analogue). Its initial administration stimulates release of gonadotropins, LH and FSH, from the anterior pituitary. This is followed by their suppressioIndications: Breast cancer; prostate cancer; endometriosis; endometrial thinning prior to endometrial ablation.n. |
| Precautions | Lactation; undiagnosed abnormal uterine bleeding; patients with ureteral obstruction or spinal cord compression should have appropriate treatment prior to initiation of therapy in male patients. |
| Contra-Indications | Pregnancy; sensitivity to goserelin and related compounds. |
| Side Effects | Most of side effects are related to hypoestrogenism in females and hypotestosteronism in males. loss of vertebral trabecular bone density in female; cardiac arrhythmias or palpitations; anaphylaxis; bone, muscle, or joint pain; paresthesias; syncope; androgenic effects; personality or behavioral changes; angina; myocardial infarction; pulmonary embolism; thrombophlebitis; amenorrhea; spotting; blurred vision; decreased libido; dizziness; oedema; headache; injection site reaction; nausea or vomit |
| Dosage | 3.6mg depot S.C into the anterior abdominal wall every 28 days. 6 months only for endometriosis. |
| Pregnancy Category | Category D |
| Pregnancy Category Description | Drugs, which have caused, are suspected to have caused, or may be expected to cause an increased rise in the frequency of malformations or irreversible damage. These drugs may also have adverse pharmacological effects required required |